Log In
Print this Print this

Delzicol, mesalamine

  Manage Alerts
Collapse Summary General Information
Company Allergan plc
DescriptionDelayed-release formulation of 5-aminosalicylate (5-ASA) mesalamine
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationInflammatory bowel disease (IBD)
Indication DetailsTreat mildly to moderately active ulcerative colitis
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today